Vor Biopharma Inc. — Q2 2022 Form 10-Q
Business context and reporting period. This clinical-stage cell and genome engineering company reported results for the quarter and six months ended June 30, 2022. It has no approved products and has generated no product revenue. Its lead program, VOR33, is being evaluated in a Phase 1/2a trial for AML; VCAR33 programs are also in development.
Financial condition and results
| Metric | Q2 2022 | Six months 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | None | None | None |
| Research and development expense | $15.3 million | $30.6 million | $13.0 million; $21.9 million |
| General and administrative expense | $6.5 million | $14.0 million | $5.4 million; $10.2 million |
| Net loss | $21.7 million | $44.4 million | $18.4 million; $32.1 million |
| Net loss per share, basic and diluted | $0.58 | $1.19 | $0.50; $1.13 |
| Operating cash used | Not stated for quarter | $47.9 million | $34.2 million |
Operating expenses rose year over year, primarily reflecting higher staffing, research and development activity, and expanded laboratory, cGMP manufacturing and office facilities. Interest income increased, but remained small relative to operating expenses. Profit margins are not meaningful because the company has no revenue.
At June 30, cash and cash equivalents were $63.0 million and marketable securities were $88.1 million, totaling $151.1 million; restricted cash of $2.4 million is additional but not included in that total. Current assets were $158.8 million and current liabilities were $12.3 million. The company reported no debt. Stockholders’ equity was $175.0 million and accumulated deficit was $174.5 million.
Cash, cash equivalents and restricted cash decreased $56.8 million during the first half. Investing activities used $9.8 million, including $7.8 million of property and equipment purchases; financing activities provided $0.8 million. Available-for-sale investments had $1.3 million in unrealized losses, attributed to higher market interest rates; no credit losses were recorded.
Changes versus prior comparable periods
- Q2 operating expenses increased $3.4 million year over year; first-half expenses increased $12.5 million. First-half net loss increased $12.3 million.
- First-half operating cash use increased $13.7 million year over year. In contrast, investing cash use declined from $77.2 million to $9.8 million, while financing cash inflows fell from $232.4 million to $0.8 million, largely because the prior-year period included the IPO and preferred-stock financing.
- Cash and cash equivalents declined from $119.8 million at year-end 2021 to $63.0 million; marketable securities were broadly stable at $88.1 million versus $87.7 million.
- Operating lease right-of-use assets increased to $46.1 million from $15.7 million, and total lease liabilities increased to $41.8 million from $18.0 million, reflecting new lease amendments and additional space.
Outlook, risks and other notable items
- Management estimated that June 30 cash, cash equivalents and marketable securities would fund operations and capital expenditures into the first quarter of 2024. The financial-statement note separately says resources are expected to cover at least one year after issuance. Management cautions that its runway estimate depends on assumptions and could be shorter than projected.
- Management expected initial VOR33 trial data in Q4 2022. Initial VCAR33 AUTO proof-of-concept data were expected in 2022, subject to the trial sponsor’s timing. The company planned to submit an IND for VCAR33 ALLO in the first half of 2023 and said it would await initial VOR33 and VCAR33 ALLO data before submitting an IND for the combined Treatment System.
- The company expects significant future operating losses and increased research, development and facility spending; additional capital will be needed. A $350 million shelf registration statement and a $125 million at-the-market facility provide potential financing capacity. About $124.4 million remained available under the ATM at quarter-end; approximately $0.6 million of net proceeds had been raised under it.
- COVID-19 had contributed to VOR33 trial site-readiness and enrollment delays. Further risks include clinical and regulatory uncertainty, patient enrollment, manufacturing and supply-chain disruptions, competition, intellectual-property dependence, and the possibility of needing financing on unfavorable terms or being unable to obtain it.
- New lease obligations increased contractual commitments by $31.5 million, including $1.4 million due within 12 months. No material legal proceedings or material changes to the previously disclosed risk factors were reported. Management concluded disclosure controls were effective as of June 30, 2022.
Investor verification priorities
- Track VOR33 enrollment and the timing and results of the anticipated clinical readout, alongside VCAR33 AUTO data and the planned VCAR33 ALLO IND.
- Reassess the cash runway against actual operating cash use, planned R&D and capital spending, and the stated Q1 2024 estimate.
- Confirm future ATM or other financing activity, remaining shelf capacity, and potential shareholder dilution.
- Review the scale and timing of new lease payments and facility commitments, as well as any further changes in lease liabilities.
- Monitor clinical, regulatory, COVID-19, manufacturing and financing risks that could delay development or shorten the runway.